Two years of adjuvant androgen deprivation therapy (ADT) combined with high-dose radiotherapy improves control and overall survival in high-risk patients with prostate cancer compared to short-term ADT, according to a recent study published in The Lancet Oncology.
Spanish researchers led by Almudena Zapatero, PhD, of the Hospital Universitario de la Princesa conducted an open-label, multicenter, phase 3 randomized controlled trial from November 2005 to December 2010. They examined 178 patients with prostate cancer who received short-term ADT and 177 who received long-term ADT.
Median follow-up was 63 months, and the primary endpoint was biochemical disease-free survival.
The researchers found that 5-year biochemical disease-free survival, 5-year overall survival and 5-year metastasis-free survival were all significantly better in patients who received long-term ADT compared to short-term.
Additionally, they found that the effect of long-term ADT on survival was more evident in patients with high-risk disease compared to low-risk patients.
The researchers aimed to determine whether long-term androgen deprivation was superior to short-term androgen deprivation when combined with high-dose radiotherapy. Longer follow–up is needed to determine whether men with intermediate–risk disease benefit from more than 4 months of androgen deprivation.